FDA approves expansion of MDMA therapy
The Multidisciplinary Association for Psychedelic Studies has been granted approval for an expanded access programme of MDMA-assisted psychotherapy. The US Food and Drug Administration (FDA) approval means that patients will be eligible for access to MDMA treatments under investigation if those patients have a serious or life-threatening condition, if other therapies have not worked and if they do not qualify for participation in Phase 3 clinical trials.